Effectiveness and safety of TNF inhibitors in adults with juvenile idiopathic arthritis.

Lianne Kearsley-FleetFlora McErlaneHelen E FosterMark LuntKath D WatsonDeborah P M SymmonsKimme L Hyrich

Published in: RMD open (2016)

This is the largest study to describe disease activity and safety outcomes in adults with JIA receiving TNFi. Disease activity improved after 1 year in all disease patterns, suggesting TNFi is an effective therapy in this population.

Keyphrases

disease activity
juvenile idiopathic arthritis
rheumatoid arthritis
systemic lupus erythematosus
rheumatoid arthritis patients
ankylosing spondylitis
metabolic syndrome
skeletal muscle
mesenchymal stem cells
weight loss